Glimepiride

Generic Name
Glimepiride
Brand Names
Duetact, Tandemact
Drug Type
Small Molecule
Chemical Formula
C24H34N4O5S
CAS Number
93479-97-1
Unique Ingredient Identifier
6KY687524K
Background

First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...

Indication

Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

First Posted Date
2009-11-03
Last Posted Date
2016-04-13
Lead Sponsor
Takeda
Target Recruit Count
426
Registration Number
NCT01007097

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment

First Posted Date
2009-07-30
Last Posted Date
2012-08-21
Lead Sponsor
Sanofi
Target Recruit Count
708
Registration Number
NCT00949442
Locations
🇰🇼

Investigational Site Number 414001, Kuwait, Kuwait

🇷🇴

Investigational Site Number 642005, Iasi, Romania

🇷🇴

Investigational Site Number 642010, Oradea, Romania

and more 84 locations

Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus

First Posted Date
2009-07-17
Last Posted Date
2010-05-18
Lead Sponsor
Laboratorios Silanes S.A. de C.V.
Target Recruit Count
28
Registration Number
NCT00941161
Locations
🇲🇽

Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Effect of Sitagliptin on Postprandial Lipoprotein Metabolism

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2009-07-15
Last Posted Date
2011-06-27
Lead Sponsor
Ludwig-Maximilians - University of Munich
Target Recruit Count
3
Registration Number
NCT00939939
Locations
🇩🇪

Medical Dept. 2, Grosshadern, University Munich, Munich, Germany

Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-05-27
Last Posted Date
2012-08-08
Lead Sponsor
Sanofi
Target Recruit Count
391
Registration Number
NCT00908921
Locations
🇨🇳

Sanofi-Aventis Administrative Office, Shanghai, China

Study of the Durability of Glycemic Control With Nateglinide

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-03-09
Last Posted Date
2017-05-16
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
88
Registration Number
NCT00858013
Locations
🇰🇷

Korea University Guro Hospital, Seoul, Korea, Republic of

🇰🇷

Kyung hee University Medical Center, Seoul, Korea, Republic of

🇰🇷

Hanyang University Medical Center, Guri-si, Kyunggi-do, Korea, Republic of

and more 4 locations

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

First Posted Date
2009-02-12
Last Posted Date
2016-10-17
Lead Sponsor
AstraZeneca
Target Recruit Count
18
Registration Number
NCT00842556
Locations
🇺🇸

Ppd Development, Austin, Texas, United States

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

First Posted Date
2009-02-09
Last Posted Date
2017-01-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
685
Registration Number
NCT00839527
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

First Posted Date
2009-02-09
Last Posted Date
2017-01-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1049
Registration Number
NCT00838903
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath